September 22, 2022

Maze Therapeutics

Maze Therapeutics Appoints Sekar Kathiresan, M.D., to its Board of Directors

September 22, 2022

Celsius Therapeutics

Celsius Therapeutics Names Scientific Advisers

September 22, 2022


Septerna Appoints Jeffrey Finer, MD, PhD, as Chief Executive Officer

September 22, 2022

Revolution Medicines

Revolution Medicines Doses First Patient in Phase 1/1b Clinical Trial of RMC-6291, Company’s First Mutant-Selective RAS(ON) Inhibitor

September 20, 2022

Decibel Therapeutics

Decibel Therapeutics Announces Submission of Investigational New Drug (IND) Application for Lead Gene Therapy Candidate DB-OTO

Load More

Sign up for weekly portfolio news.